Challenges in the diagnosis of neurofibromatosis type 1 (NF1) in young children facilitated by means of revised diagnostic criteria including genetic testing for pathogenic NF1 gene variants
Abstract:Neurofibromatosis type 1 (NF1) is the most frequent disorder associated with multiple café-au-lait macules (CALM) which may either be present at birth or appear during the first year of life. Other NF1-associated features such as skin-fold freckling and Lisch nodules occur later during childhood whereas dermal neurofibromas are rare in young children and usually only arise during early adulthood. The NIH clinical diagnostic criteria for NF1, established in 1988, include the most common NF1-associated features.… Show more
“…This is remarkable since the children are often too young at the onset of JMML to display the full spectrum of NF-1-associated symptoms. 5,36 In fact, our genetic data show that the presence of ≥6 café-au-lait macules (or less in the case of affected parents) in a child with JMML is already sufficient to diagnose NF-1 with a very high probability.…”
SummaryJuvenile myelomonocytic leukaemia (JMML) is characterized by gene variants that deregulate the RAS signalling pathway. Children with neurofibromatosis type 1 (NF‐1) carry a defective NF1 allele in the germline and are predisposed to JMML, which presumably requires somatic inactivation of the NF1 wild‐type allele. Here we examined the two‐hit concept in leukaemic cells of 25 patients with JMML and NF‐1. Ten patients with JMML/NF‐1 exhibited a NF1 loss‐of‐function variant in combination with uniparental disomy of the 17q arm. Five had NF1 microdeletions combined with a pathogenic NF1 variant and nine carried two compound‐heterozygous NF1 variants. We also examined 16 patients without clinical signs of NF‐1 and no variation in the JMML‐associated driver genes PTPN11, KRAS, NRAS or CBL (JMML‐5neg) and identified eight patients with NF1 variants. Three patients had microdeletions combined with hemizygous NF1 variants, three had compound‐heterozygous NF1 variants and two had heterozygous NF1 variants. In addition, we found a high incidence of secondary ASXL1 and/or SETBP1 variants in both groups. We conclude that the clinical diagnosis of JMML/NF‐1 reliably indicates a NF1‐driven JMML subtype, and that careful NF1 analysis should be included in the genetic workup of JMML even in the absence of clinical evidence of NF‐1.
“…This is remarkable since the children are often too young at the onset of JMML to display the full spectrum of NF-1-associated symptoms. 5,36 In fact, our genetic data show that the presence of ≥6 café-au-lait macules (or less in the case of affected parents) in a child with JMML is already sufficient to diagnose NF-1 with a very high probability.…”
SummaryJuvenile myelomonocytic leukaemia (JMML) is characterized by gene variants that deregulate the RAS signalling pathway. Children with neurofibromatosis type 1 (NF‐1) carry a defective NF1 allele in the germline and are predisposed to JMML, which presumably requires somatic inactivation of the NF1 wild‐type allele. Here we examined the two‐hit concept in leukaemic cells of 25 patients with JMML and NF‐1. Ten patients with JMML/NF‐1 exhibited a NF1 loss‐of‐function variant in combination with uniparental disomy of the 17q arm. Five had NF1 microdeletions combined with a pathogenic NF1 variant and nine carried two compound‐heterozygous NF1 variants. We also examined 16 patients without clinical signs of NF‐1 and no variation in the JMML‐associated driver genes PTPN11, KRAS, NRAS or CBL (JMML‐5neg) and identified eight patients with NF1 variants. Three patients had microdeletions combined with hemizygous NF1 variants, three had compound‐heterozygous NF1 variants and two had heterozygous NF1 variants. In addition, we found a high incidence of secondary ASXL1 and/or SETBP1 variants in both groups. We conclude that the clinical diagnosis of JMML/NF‐1 reliably indicates a NF1‐driven JMML subtype, and that careful NF1 analysis should be included in the genetic workup of JMML even in the absence of clinical evidence of NF‐1.
“…In addition to CALMs, axillary and inguinal freckling also occur in >90% of patients by the age of 7 years. 7 Bone and eye abnormalities such as sphenoid wing dysphasia and Lisch nodules in the eyes also serve as other signs of this condition. 8…”
Although most primary central and peripheral nervous system (NS) tumors occur sporadically, there are a subset that may arise in the context of a cancer predisposition syndrome. These syndromes occur due to a pathogenic mutation in a gene that normally functions as a tumor suppressor. With increased understanding of the molecular pathogenesis of these tumors, more people have been identified with a cancer predisposition syndrome. Identification is crucial, as this informs surveillance, diagnosis, and treatment options. Moreover, relatives can also be identified through genetic testing. Although there are many cancer predisposition syndromes that increase the risk of NS tumors, in this review, we focus on three of the most common cancer predisposition syndromes, neurofibromatosis type 1, neurofibromatosis type 2, and tuberous sclerosis complex type 1 and type 2, emphasizing the clinical manifestations, surveillance guidelines, and treatment options.
“…A cutan neurofibromák, melyek sohasem válnak rosszindulatúvá, általában felnőttkorban jelennek meg, és a neurofibromatosis-1-ben szenvedő felnőtt populáció 80-90%-ában fordulnak elő [40]. A microdeletiós betegcsoportra azonban jellemző a cutan neurofibromák nagy száma és korai (pubertás előtti) megjelenése [27,41]. A cutan neurofibromák mellett gyakran subcutan neurofibromák is kialakulhatnak.…”
Az 1-es típusú neurofibromatosis autoszomális domináns öröklésmenetet mutató,
klinikailag rendkívül heterogén neurocutan kórkép, amelynek kialakulásában
elsődlegesen az NF1-gén intragenikus funkcióvesztéses mutációi
játszanak szerepet. Ugyanakkor a molekuláris diagnosztika fejlődésének
köszönhetően egyre több esetben sikerül kimutatni az NF1-gént
és az azzal szomszédos régiókat érintő kópiaszámbeli variánsokat.
Genotípus-fenotípus elemzések alapján a pontmutációs eltérések okozta 1-es
típusú neurofibromatosis, illetve a microdeletiós eltérések okozta, ún. 17q11.2
microdeletiós szindróma elkülöníthetők egymástól. Microdeletiók az esetek
5–10%-ában figyelhetők meg, melyek méretük, töréspontjaik genomi lokalizációja
és érintett géntartalmuk alapján négy különböző típusba (1-es, 2-es, 3-as és
atípusos) sorolhatók. A microdeletiós betegek gyakran súlyosabb kórlefolyást
mutatnak, melyből kiemelendő a malignitások emelkedett kockázata. Az
összefoglaló közleménnyel, mely a neurofibromatosis-1 microdeletiós szindróma
főbb jellemzőit, molekuláris genetikai hátterét és vizsgálati módszereit
tárgyalja, a microdeletiós szindrómás betegek korai diagnózishoz jutásának
fontosságát szeretnénk hangsúlyozni és felhívni a figyelmet a szoros nyomon
követés jelentőségére. Orv Hetil. 2022; 163(51): 2041–2051.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.